title: Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier.
abstract: BACKGROUND
  The optimal blood pressure target in patients with chronic kidney disease (CKD) is unclear.
  
  
  OBJECTIVE
  To summarize trials comparing lower versus higher blood pressure targets in adult patients with CKD and focus on proteinuria as an effect modifier.
  
  
  METHODS
  MEDLINE and the Cochrane Central Register of Controlled Trials (July 2001 through January 2011) were searched for reports from randomized, controlled trials with no language restriction.
  
  
  METHODS
  Authors screened abstracts to identify reports from trials comparing blood pressure targets in adults with CKD that had more than 50 participants per group; at least 1-year follow-up; and outcomes of death, kidney failure, cardiovascular events, change in kidney function, number of antihypertensive agents, and adverse events.
  
  
  METHODS
  Reviewers extracted data on study design, methods, sample characteristics, interventions, comparators, outcomes, number of medications, and adverse events and rated study quality and quality of analyses for proteinuria subgroups.
  
  
  RESULTS
  Three trials with a total of 2272 participants were included. Overall, trials did not show that a blood pressure target of less than 125/75 to 130/80 mm Hg is more beneficial than a target of less than 140/90 mm Hg. Lower-quality evidence suggests that a low target may be beneficial in subgroups with proteinuria greater than 300 to 1000 mg/d. Participants in the low target groups needed more antihypertensive medications and had a slightly higher rate of adverse events.
  
  
  CONCLUSIONS
  No study included patients with diabetes. Trial duration may have been too short to detect differences in clinically important outcomes, such as death and kidney failure. Ascertainment and reporting of adverse events was not uniform.
  
  
  CONCLUSIONS
  Available evidence is inconclusive but does not prove that a blood pressure target of less than 130/80 mm Hg improves clinical outcomes more than a target of less than 140/90 mm Hg in adults with CKD. Whether a lower target benefits patients with proteinuria greater than 300 to 1000 mg/d requires further study.
authors.affiliation: Tufts University School of Medicine, Boston, MA, USA.
authors.forename: Ashish
authors.initials: A
authors.lastname: Upadhyay
authors.forename: Amy
authors.initials: A
authors.lastname: Earley
authors.forename: Shana M
authors.initials: SM
authors.lastname: Haynes
authors.forename: Katrin
authors.initials: K
authors.lastname: Uhlig
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000503:physiopathology* / Q000652:urine; D011507:Proteinuria; D012107:Research Design / Q000592:standards; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents